Key facts
- It has raised $22.4M; the latest was Later Stage VC ($11.6M) in Dec 2025.
- Notable investors include InnovationQuarter, Van Herk Groep, Erasmus MC, Health ~ Holland, Swanbridge Capital — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Pan Cancer T
- ·The full record, as it builds
Funding rounds
No funding rounds for Pan Cancer T are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Pan Cancer T
Developer of T-cell therapies designed to provide treatment options for hard-to-treat solid cancers through adoptive therapy. The company's therapies are genetically engineered with TCRs to exploit the ability of the immune cells, to specifically and efficiently recognize and kill malignant cells according to the expression of intracellular target antigens, enabling patients to receive treatments to maximize the efficacy of TCR T-cells towards solid tumors.
- Sector
- Healthcare
- HQ
- Rotterdam, Netherlands
- Founded
- 2020
- Employees
- 8
- Website
- pancancer-t.com/
- Ownership
- Privately Held (backing)
Pan Cancer T doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Pan Cancer T shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Pan Cancer T in its N-PORT filings yet. We sweep new filings monthly.